Singlecare: Can hand sanitizers or hand-washing kill the flu?
Dr. Carl Fichtenbaum says it's what you do with your hands when cleaning them that's important
New research examines what is more effective against the flu: hand sanitizer or hand washing. The study found that when the flu virus is trapped in wet mucus, it can remain infectious for up to four minutes after exposure to hand sanitizer—in other words, much longer than you might have guessed. According to the study, hand-washing—even without soap and even when the infected mucus was wet—was, indeed, very effective in removing the flu virus. It eliminated it in just 30 seconds.
Dr. Carl Fichtenbaum of the Division of Infectious Diseases in the UC College of Medicine, in an interview with Singlecare, said "the fight wasn't fair." He says researchers didn’t study how hand sanitizer works when it’s rubbed into the skin, only when it was dabbed onto fingers, adding "hand rubbing is the critical part of all this."
Additional Contacts
Related Stories
Taking a second look at surgery eligibility for patients with lung cancer who smoke
June 11, 2026
Researchers at the University of Cincinnati College of Medicine have found that patients who continue to smoke ahead of lung cancer surgery have a higher risk of pulmonary complications, but their short-term mortality rate is similar to patients who were able to stop smoking before surgery.. Their findings were published recently in the Journal of. American College of Surgeons
Patients with developmental disabilities may benefit with an integrated care model
June 9, 2026
Researchers from the University of Cincinnati and Ohio State University have found that adults with developmental disabilities who have integrated care were less likely to go to the emergency room or be hospitalized than others who were not. Their work was published in Disability and Health Journal.
UC physician-researcher's work yields landmark five-year data for Crohn's disease drug
June 8, 2026
The University of Cincinnati College of Medicine’s Anita Afzali, MD, leads a landmark study revealing five-year efficacy and safety data for a Crohn’s disease drug called guselkumab.